Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Leukemia 22Lymphoma 14Leukemia, Myeloid, Acute 14Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Breast Neoplasms 11Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Multiple Myeloma 9Melanoma 9Lymphoma, Follicular 9Neuroblastoma 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Ovarian Neoplasms 7Congenital Abnormalities 7Lymphoma, Non-Hodgkin 6Hodgkin Disease 5Neoplasms, Plasma Cell 4Neoplasm Metastasis 4Myeloproliferative Disorders 4Lymphoma, Mantle-Cell 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4Fallopian Tube Neoplasms 4Anemia, Refractory, with Excess of Blasts 4Waldenstrom Macroglobulinemia 3Osteosarcoma 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, B-Cell, Marginal Zone 3

Interventions

Tamoxifen 9Letrozole 5Anastrozole 5Radiotherapy 3Radiation 3Neoadjuvant Therapy 3afimoxifene 2Trastuzumab 2Surgical Procedures, Operative 2Simvastatin 2Sentinel Lymph Node Biopsy 2Radiation Dose Hypofractionation 2Mastectomy, Segmental 2Lapatinib 2Gene Expression Profiling 2trastuzumab biosimilar HLX02 1telapristone acetate 1sargramostim 1polyphenon E 1pasireotide 1palbociclib 1oxybutynin 1liposomal doxorubicin 1exemestane 1Zoledronic Acid 1UAB 30 1Tea 1Sugars 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Intraductal, Noninfiltrating × sargramostim × Clear all
NCT02636582 2023-12-05

Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer

National Cancer Institute (NCI)

Phase 2 Completed
43 enrolled 10 charts
Breast

Carcinoma, Intraductal, Noninfiltrating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡